DRREDDY Q1 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: high)
Earnings Summary
Dr. Reddy's Q1FY27 was sharply impacted by a ₹240 cr semaglutide API provision and lower lenalidomide sales, causing a 5.6% YoY revenue decline and EBITDA margin of 12.5%. However, the underlying base business grew double-digit across all regions (NA, India, Emerging Markets). Management expects a strong H2 recovery with semaglutide resumption by November, targeting a ~20% EBITDA margin ex-semaglutide. Key catalysts: abatacept approval (Dec 2026), new US launches, and cost productivity. Risks: semaglutide API fix execution, Middle East conflict, and US generic pricing pressure. , ,
Management Tone
- Prepared Remarks: Good — Management described strong underlying base business growth (double-digit across geographies), new product launches (bosutinib, nintedanib), and a clear plan to resume semaglutide by November, expressing confidence in a strong H2. The tone was measured but optimistic about the core strategy. ,
- Q&A Session: Neutral — Analysts focused on the semaglutide situation (root cause, competition, volume loss), margin sustainability, and abatacept approval risks. Management's responses were direct and provided quantification (e.g., 180,000 pens sold, 6-7 million target), but acknowledged uncertainties (80-90% success rate
Revenue Growth Drivers
- Lower lenalidomide sales (one-off base effect)
- Semaglutide API provision (₹240 cr) and lost sales,
- Strong double-digit underlying growth across NA, India, Emerging Markets, ,
Growth vs Margin Focus
Management balanced focus: targeting double-digit revenue growth while maintaining 'neighbourhood of 20%' EBITDA margin ex-semaglutide, and guiding for low single-digit cost growth vs. double-digit sales growth. They aim to grow branded markets (52% of revenue) which provide stable margins. ,
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (DRREDDY) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.